Shopping Cart

Your shopping cart is currently empty

MRE-269

Name: MRE-269
Brand: TargetMol
SKU: T3S2007
Price: 47 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Catalog No. T3S2007Cas No. 475085-57-5

Alias MRE269, MRE 269, ACT-333679

MRE-269 (ACT-333679) is an orally available and long-acting prostacyclin receptor agonist prodrug. MRE-269(ACT-333679) is used for the treatment of pulmonary arterial hypertension. MRE-269(ACT-333679) is an active metabolite of Selexipag (S253150).

MRE-269

Copy Product Info

🥰Excellent

Purity: 98.25%

Catalog No. T3S2007Alias MRE269, MRE 269, ACT-333679Cas No. 475085-57-5

Pack Size	Price	USA Warehouse	Global Warehouse
5 mg	$47	In Stock	In Stock
10 mg	$89	In Stock	In Stock
25 mg	$143	In Stock	In Stock
50 mg	$196	In Stock	In Stock
100 mg	$330	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$52	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:98.25%

Appearance:Solid

Color:White

Resource Download

COA LCMS HNMR

Product Introduction

MRE-269 AI Summary

MRE-269 exhibits a range of bioactivities across different assays and models. It notably inhibits platelet aggregation with an IC50 of 200.0 nM in human platelet rich plasma and 288.0 nM in human primary platelets, indicating potential for targeting platelet-related disorders. The compound also interacts with prostaglandin receptors, showing 80.0% intrinsic activity and an EC50 of 154.0 nM at the human DP1 receptor, and 60.0% intrinsic activity with an EC50 of 22.0 nM at the human IP receptor. Pharmacokinetic data reveal compound 406183 has a Tmax of 2.3 hours and a Cmax of 250.28 nM in cynomolgus monkeys at 1 mg/kg oral administration, with half-lives ranging from 4.9 to 6.2 hours across different models, high oral bioavailability (80.0% to 102.0%), and significant AUC values. It exhibits moderate antiviral activity against SARS-CoV-2 with low inhibition rates in both protease assays and cytotoxicity models. Binding affinity studies show activity primarily at high nanomolar concentrations (>30,000 nM), except for a moderately lower AC50 of 10,103.5 nM at the human ADORA3 receptor. Additionally, the compound demonstrates variable effects on cell viability and protein stability, highlighted by differing growth rates in cell viability assays and mixed effects on protein melting temperatures in thermal shift assays. These diverse bioactivities suggest that MRE-269 may have multifaceted therapeutic potential, particularly in platelet inhibition and prostaglandin receptor modulation..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	MRE-269 (ACT-333679) is an orally available and long-acting prostacyclin receptor agonist prodrug. MRE-269(ACT-333679) is used for the treatment of pulmonary arterial hypertension. MRE-269(ACT-333679) is an active metabolite of Selexipag (S253150).
Targets&IC50	IP receptor (human):20 nM(Ki)
Synonyms	MRE269, MRE 269, ACT-333679

Chemical Properties

Molecular Weight	419.52
Formula	C₂₅H₂₉N₃O₃
Cas No.	475085-57-5
Smiles	N(CCCCOCC(O)=O)(C(C)C)C=1N=C(C(=NC1)C2=CC=CC=C2)C3=CC=CC=C3
Relative Density.	1.160 g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 55 mg/mL (131.1 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+90% Corn Oil: 2.5 mg/mL (5.96 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.3837 mL	11.9184 mL	23.8368 mL	119.1838 mL
5 mM	0.4767 mL	2.3837 mL	4.7674 mL	23.8368 mL
10 mM	0.2384 mL	1.1918 mL	2.3837 mL	11.9184 mL
20 mM	0.1192 mL	0.5959 mL	1.1918 mL	5.9592 mL
50 mM	0.0477 mL	0.2384 mL	0.4767 mL	2.3837 mL
100 mM	0.0238 mL	0.1192 mL	0.2384 mL	1.1918 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc